Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have been given an average rating of "Moderate Buy" by the sixteen analysts that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $55.36.

Several research analysts recently issued reports on the stock. Royal Bank of Canada reiterated an "outperform" rating and set a $54.00 price target on shares of Intellia Therapeutics in a research report on Thursday, September 19th. The Goldman Sachs Group decreased their price target on shares of Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th. StockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a research report on Friday, November 8th. Citigroup decreased their price objective on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. Finally, Evercore ISI upgraded Intellia Therapeutics to a "strong-buy" rating in a research report on Friday, August 9th.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares of the company's stock, valued at approximately $893,698.12. This represents a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.20% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its position in shares of Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock worth $105,700,000 after buying an additional 780,754 shares during the period. Vanguard Group Inc. boosted its position in Intellia Therapeutics by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company's stock worth $250,168,000 after acquiring an additional 746,263 shares during the last quarter. ARK Investment Management LLC grew its stake in shares of Intellia Therapeutics by 5.7% during the 3rd quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company's stock worth $251,849,000 after acquiring an additional 659,651 shares in the last quarter. Federated Hermes Inc. boosted its holdings in Intellia Therapeutics by 19.2% during the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company's stock worth $51,494,000 after purchasing an additional 371,189 shares during the last quarter. Finally, Two Sigma Advisers LP grew its position in Intellia Therapeutics by 33.5% in the third quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company's stock valued at $21,118,000 after purchasing an additional 257,700 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Stock Down 7.6 %

Intellia Therapeutics stock traded down $1.15 on Friday, hitting $13.97. The company's stock had a trading volume of 3,689,284 shares, compared to its average volume of 1,681,978. Intellia Therapeutics has a one year low of $13.95 and a one year high of $34.87. The firm has a market cap of $1.42 billion, a P/E ratio of -2.57 and a beta of 1.81. The company has a fifty day moving average price of $18.64 and a 200-day moving average price of $22.04.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. The company's revenue for the quarter was down 24.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.38) EPS. Analysts anticipate that Intellia Therapeutics will post -5.13 EPS for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.